sellWeak cluster of 2
MCENANY PATRICK J sold $12M of CPRX
director, other at CATALYST PHARMACEUTICALS, INC.. 492,000 shares at an average of $23.39, traded Nov 11, 2024, filed Nov 13, 2024.
Warning score
38Value
$12M
492,000 shares
Holdings after
4,478,169
-10% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001161697-24-000445, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | MOption exercise Common stock, par value $0.001 per share | +230,000 | $4.01 | $922k | 4,708,169 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common stock, par value $0.001 per share | -230,000 | $23.55 | $5.4M | 4,478,169 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Common stock, par value $0.001 per share | +70,000 | $4.01 | $281k | 4,548,169 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Common stock, par value $0.001 per share | -70,000 | $23.42 | $1.6M | 4,478,169 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Common stock, par value $0.001 per share | +192,000 | $3.54 | $680k | 4,670,169 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Common stock, par value $0.001 per share | -192,000 | $23.20 | $4.5M | 4,478,169 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Options to purchase common stockderivative | -230,000 | $0.00 | $0 | 2,362,745 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Options to purchase common stockderivative | -70,000 | $0.00 | $0 | 2,292,745 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Options to purchase common stockderivative | -192,000 | $0.00 | $0 | 2,100,745 | Nov 13, 2024 |
Related signals
Other insiders at CATALYST PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 40Moderate | sell 4 | CPRX CATALYST PHARMACEUTICALS, INC. | Miller Steve Chief Op. & Scientific Officer | $1.1M | 50,000 | |
| 29Weak | sell 5 | CPRX CATALYST PHARMACEUTICALS, INC. | Elsbernd Brian Chief Compliance/Legal Officer | $287k | 13,256 | |
| 51Moderate | sell 5 | CPRX CATALYST PHARMACEUTICALS, INC. | Harper Molly director | $385k | 17,500 | |
| 33Weak | sell 5 | CPRX CATALYST PHARMACEUTICALS, INC. | INGENITO GARY Chief Med. & Reg. Officer | $273k | 12,000 | |
| 47Moderate | sell 4 | CPRX CATALYST PHARMACEUTICALS, INC. | INGENITO GARY Chief Med. & Reg. Officer | $806k | 38,000 | |
| 40Moderate | sell 4 | CPRX CATALYST PHARMACEUTICALS, INC. | MCENANY PATRICK J director, other | $3.6M | 170,845 | |
| 40Moderate | sell 4 | CPRX CATALYST PHARMACEUTICALS, INC. | MCENANY PATRICK J director, other | $3.1M | 137,155 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.